Transforming Healthcare Through Innovation

MISSION

The primary mission of VacciMed-Oral GmbH is to develop and commercialize an oral vaccination platform based on patented VSP-VLP (Variable Surface Proteins – Viral-Like Particles) technology. This platform is intended for human and veterinary health use, offering a revolutionary approach to vaccine administration. The company’s key objectives include:

  • Development of Oral Vaccination Platform: VacciMed-Oral GmbH aims to develop and validate an oral vaccination platform for veterinary and human health, leveraging the patented VSP-VLP technology. The goal is to obtain approval from health authorities and facilitate global marketing.
  • Novel Oral Vaccines: The company is dedicated to developing novel oral vaccines against infectious diseases, including influenza (flu) and SARS-CoV-2 (Covid-19). These vaccines have demonstrated excellent results in animal models, protecting against infections and inhibiting virus transmission.
  • Application in the Veterinary Sector: VacciMed-Oral GmbH plans to extend the versatile oral vaccine platform to the veterinary sector, addressing the need for effective and efficient vaccination against viral diseases, for example, in fish and poultry farms.
  • Oral Administration of Therapeutic Peptides: The company seeks to bring biological drugs, such as insulin, growth hormone, and other therapeutic peptides, to the market using an innovative method that allows oral administration. This approach aims to overcome the challenges associated with continuous injections.

Key Strategies and Differentiators:

  • Innovative Antigenic Variation Technology: Our groundbreaking approach induces antigenic variation within protozoan parasites, resulting in superior vaccine effectiveness compared to traditional methods.
  • Versatility Across Parasites: We adapt seamlessly to various protozoan parasites, making our vaccines effective against multiple diseases.
  • Oral Administration: We eliminate the need for injections, ensuring convenience and accessibility, particularly in regions with limited healthcare infrastructure.
  • Cross-Species Application: Our commitment spans both human and veterinary populations, setting us apart from competitors focused solely on one domain.
  • Scientific Excellence and Collaboration: Collaborations with esteemed research institutions and pharmaceutical giants fuel our drive for continuous advancement in vaccine development.
  • Global Health Impact: We strive to reduce the global burden of protozoan parasite-related diseases, enhancing global health security through scientific innovation.
  • Equity in Access: Ensuring affordability and accessibility is a cornerstone of our mission, particularly in resource-constrained regions.
  • Veterinary Sector Focus: Our innovative approach extends to supporting livestock production and animal health, broadening our reach.
  • Rigorous Clinical Validation: We instill trust in healthcare professionals and partners through state-of-the-art pre-clinical and clinical trials.
  • Global Adoption and Market Penetration: Strategic partnerships ensure our vaccines reach regions with a high prevalence of parasite infections.
  • Sustainability and Eco-friendliness: We align with global sustainability concerns in production and administration.
  • Digital Technologies: Exploring digital innovations for remote diagnosis and monitoring keeps us at the forefront of healthcare.

VALUES

  1. Hope and Healing: Our platform serves as a beacon of hope for countless individuals and animals suffering from treatable illnesses. By providing accessible and effective vaccines, we empower communities to overcome health challenges.
  2. Cost-Effectiveness: We recognize the financial burden faced by healthcare systems worldwide. Our solution offers a cost-effective alternative to traditional methods, ensuring that quality healthcare remains within reach for all.
  3. Expediency and Security: Our platform delivers vaccines swiftly and securely, addressing urgent needs while maintaining safety standards.
  4. Global Impact: With billions of lives at stake, our commitment extends across borders. We strive to tackle healthcare challenges faced by people around the world, fostering a healthier, more resilient planet.

Key Players:

  • Shareholders: The company’s current shareholders include Prof. Dr. Sebastian Springer, Industrie-Kfm Rainer Block, and Dr. Arnold Spitta (Managing Director). Prof. Dr. Hugo Luján, the Scientific Director, will become a shareholder in March 2024. Prof. Dr. Hugo Luján is an internationally recognized researcher and experienced biochemistry and cell biology professional. Prof. Luján has received awards in Argentina and abroad for his contributions to scientific innovation.
  • Scientific Advisory Board: The Scientific Advisory Board, chaired by Prof. Dr. Hugo Luján, comprises experts such as Prof. Dr. Sebastian Springer, Prof. Dr. Klaudia Brix, and Prof. Dr. Tim Sparwasser.

VacciMed-Oral GmbH is not just competing; we are pioneering change. Our journey is one of dedication, innovation, and transformation, leaving an enduring legacy of improved health and well-being for generations to come. With a strong team, strategic partnerships, and a focus on global health, the company aims to address critical challenges in human and veterinary medicine.

About Us

VacciMed-Oral GmbH is a German company dedicated to the research and development of oral vaccines and therapeutics for use in human and veterinary medicine. Through innovation and cooperation, it seeks to offer solutions to various diseases in animals and humans. The aim is to achieve products that can reach the largest possible population and thus improve the quality of life by being more efficient in production, distribution and storage.

VacciMed-Oral GmbH focuses on developing vaccines to prevent or treat protozoan parasite infections. Their approach involves creating vaccines containing multiple protozoan variable surface antigens (VSAs). These vaccines are designed to induce a broad and effective immune response against the full range of VSAs found in a given protozoan parasite. The company’s method includes cultivating protozoan parasite clones in the presence of specific antibodies to induce the expression of multiple VSAs, which are then used in the vaccine formulations.

CORE VALUES

Safety

Vaccine Development

Develop a portfolio of oral vaccines targeting various protozoan parasites.

Accessibility

Ongoing Innovation

Continuously innovate and expand our product pipeline to address additional protozoan parasites.

Innovation

Health Impact

Contribute to the reduction of protozoan parasite-related morbidity and mortality, particularly in endemic regions, and enhance the well-being of humans, animals, and livestock.

JOIN OUR JOURNEY

Investors interested in our transformative healthcare vision can engage with us in several ways:

  1. Equity Investment: Consider becoming a shareholder by investing in our company. Your capital infusion will directly support our research, development, and global outreach efforts.
  2. Partnerships: Collaborate with us! We seek strategic partnerships with organizations that share our commitment to advancing healthcare solutions. Whether it’s joint ventures, licensing agreements, or co-development projects, we welcome collaboration.
  3. Due Diligence: Review our financial reports, growth projections, and regulatory compliance. Understand our business model, competitive advantages, and risk mitigation strategies.

Remember, your investment isn’t just financial—it’s an endorsement of our mission. Together, we can drive positive change and improve lives globally. 

Let’s Talk

Investors can trust in our vision, knowing that our values drive every decision we make. Together, we’re shaping a healthier future—one vaccine at a time. 

Bonn, Germany

T: ( 202) 555-0125
E-Mail: info@vaccimed-oral.com